Viatris's second pivotal MR-142 eye drop trial data still pending past H1 2026 window
LYNX-3 must replicate LYNX-2's positive result to complete the pivotal package for a condition with no FDA-approved therapy.
Executive Summary
- Viatris is running the second of two pivotal Phase 3 trials of an eye drop intended to treat night-driving vision impairment after corrective eye surgery, a condition with no approved drug therapy.
- The first pivotal trial in this same design already met its primary vision-improvement endpoint against placebo, so the second trial's job is to reproduce that result, not establish it for the first time.
- The trial's own primary completion date has been revised twice in a single week, moving out by more than a year and then snapping back, a pattern that raises questions about how firmly the current date reflects the trial's actual data-lock status.
- No other active trial anywhere shares this drug's target in this indication, leaving the readout as the only near-term evidence on whether this mechanism works for this specific vision problem.
The trial and its job
LYNX-3 (NCT07140783) is a randomized, placebo-controlled, quadruple-masked Phase 3 trial testing MR-142, a topical alpha-adrenoceptor antagonist, in 200 adults with reduced mesopic visual acuity following keratorefractive surgery such as LASIK or PRK. The primary endpoint is the percentage of patients who gain at least 15 ETDRS letters, or three lines, in mesopic low-contrast visual acuity in the study eye at Day 15 compared to baseline. The trial is registrational and is designed as the second of two pivotal studies needed to support marketing applications for the drug. NCT07140783OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual AcuityNCT07140783
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the first trial showed
LYNX-2, the first pivotal trial in the program, read out in June 2025 and met its primary endpoint: significantly more patients on MR-142 achieved the 15-letter mLCVA gain compared to placebo at Day 15 (p<0.05), in a 199-patient randomized, double-masked study. Patients also reported less difficulty with headlight glare and dusk driving on the validated Vision and Night Driving Questionnaire, and the trial found no evidence of tachyphylaxis, a loss of drug effect with repeated dosing, over six weeks. Viatris said the drug showed a safety profile consistent with prior trials and no new safety signal. ViatrisViatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast ConditionsJun 2, 2025
The timing gap
Viatris and later Opus Genetics guided investors to a first-half-2026 LYNX-3 readout across four separate disclosures between June 2025 and March 2026, each repeating the same January-to-June 2026 window. That window closed June 30, 2026, without a disclosed result. In the interim, the trial's primary completion date was pushed from March 2026 out to August 2027 on June 17, 2026, then pulled back to June 1, 2026 five days later on June 22, 2026, the same day the trial's status changed to Active, not recruiting. The registry itself flags this as a timeline whipsaw, a delay followed by a pull-in of more than 90 days with a new completion date landing within 60 days of the change. Viatris+1Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast ConditionsJun 2, 2025OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual AcuityNCT07140783
The competitive frame
No other active trial anywhere combines this drug's alpha-adrenoceptor target with this indication, and the two Ocuphire-sponsored programs that share the same modality, Nyxol in dim-light vision disturbances and phentolamine in pharmacologically-induced mydriasis, test different targets and different conditions. No FDA-approved therapy exists for this condition. With LYNX-2 already positive and no validated pharmacologic comparator in this specific setting, the bar for LYNX-3 is replication of the LYNX-2 effect size at a similar level of statistical significance, not a novel efficacy finding.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.